Topic Listing for Insmed

Actual Results Timing Certain Events Differ Materially Discussed Additional Covenants
Additional Rights Terminate Insmeds Material Breach Such Respect Adjustment Change Common Stock
Administration Aggregated Option Exercises 2004 Year-end Values
Aggregated Option Exercises 2005 Year-end Values Agreement 2007 Between
Als Als Credit
Amendment Amendment 2000 Employee Stock Purchase Plan
Amendment Restatement 2000 Stock Incentive Plan Amendment Rights Agreement
Amendment Supplement Amendments Waivers
Annual Bonuses Annual Meeting Shareholders
Annual Report Form 10-k Asset Impairment
Assignment Assignment Contracts Rights Obligations
Assumption Liabilities Attachment
Attorneys Genentech Inc Attorneys Tercica Inc
Audit Committee Audit Committee Pre-approval Policy
Audit Committee Report Available Information
Available Information Corporate Governance Documents Avecia Limited
Background Base Salaries
Basis Presentation Beneficial Owners Shares
Beneficial Ownership Reporting Compliance Beyond Iplex Oncology Compounds
Board Directors Brokers Other Advisors
Budgets Business Experience
Business Overview Business Strategy
Canada Iplex Sales Tercica Genentech Indications Cancer
Cannot Certain Obtain Additional Regulatory Approvals United States Cannot Certain Obtain Regulatory Approvals Foreign Countries Failure
Cannot Certain Obtain Regulatory Approvals United States Europe Cannot Certain Obtain Regulatory Approvals United States European
Cannot Certain Obtain Regulatory Approvals United States Other Capital Requirements
Capital Resources Cash Equivalents
Cash Equivalents Short-term Investments Certain Covenants
Certain Covenants Purchaser Certain Factors Affect Future Results
Certain Filings Notices Sec Certain Provisions Virginia Law Articles Incorporation Amended Restated
Certain Relationships Related Transactions Certification
Certification Principal Executive Officer Certification Principal Financial Officer
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Change Control Agreement
Change Control Agreements Change Control Arrangements
Change Control Payments Clinical Study
Closing Closing Assets
Closing Assets Purchase Price Closing Assets Repurchase Right
Code Code Ethics
Commencement Agreement Lease Amendment Number Commercialization
Common Stock Common Stock Convertible Debt
Common Stock Delisted Nasdaq Capital Market Cause Value Common Stock Delisted Nasdaq Global Market Price Continues
Common Stock Subject Plan Common Stock Thinly Traded Time Means Large Transactions
Communications Board Companies Partner Through License Development Agreement
Compared 2002 Compared 2003
Compared 2004 Compared 2005
Compared 2006 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Executive Officers 2006 Compensation Program Components
Competition Competition Iplex
Competition Other Drug Candidates Competitors Develop Gain Fda Approval Products Containing Rhigf-1
Completed Clinical Study Compliance Laws Permits
Components Compensation Comprehensive Loss
Condemnation Condition
Conditions Closing Conditions Each Party8217s Obligation Effect Closing Transactions
Conditions Obligations Underwriters Conditions Parent8217s Purchaser8217s Obligation Effect Closing Transactions
Conditions Seller8217s Obligation Effect Closing Transactions Conference Call
Conference Call 800am Conference Call Tomorrow 800am Est
Confidentiality Confidentiality Agreements Employees Others Not Adequately Prevent Disclosure
Conflicts Between Collaborative Partners Adverse Effect Business Financial Consecutive Business 2008
Consent Independent Registered Public Accounting Firm Contractual Obligations
Controls Procedures Conversion Notes
Conversion Outstanding Notes Exercise Warrants Options Issued Significantly Convertible Debt Financing
Convertible Debt Financings Corporate Governance Management
Corporate Governance Matters Corporate History
Cost Soliciting Proxies Counterparts
Court Dismisses Baseless Unfair Business Practices Lawsuit Was Critical Accounting Policies
Current Direction Currently Defendant Civil Action Accused Deceptive Promotional Statements
Currently Limited Sales Marketing Distribution Capabilities Make Commercializing Damage Destruction
Data Presented Oral Presentation Pediatric Academic Societies 2006 Deceptive Promotional Statements Unfair Business Practice Litigation
Deceptive Promotional Statements Unfair Business Practices Claims Deductibility Compensation
Defaulting Underwriter Defaults Tenant
Definitions Definitions Demise Premises
Deliveries Purchaser Closing Deliveries Seller Closing
Delivery Funds Delivery Shares
Departure Directors Principal Officers Election Appointment Dependent Retaining Attracting Key Personnel Others Loss Materially
Description Business Summary Significant Accounting Policies Designation Auditors
Development Hiv-related Condition Myotonic Muscular Dystrophy Development Iplex Hars
Development Iplex Mmd Development Iplex Myotonic Muscular Dystrophy
Development Iplex Rop Development Opt-in Rights
Diabetes Diabetes Extension Studies Related Extreme Insulin Resistance Longer-term
Director Compensation Director Compensation 2006
Director Compensation 2007 Director Nominating Process
Director Option Grants Director Whose Term Expires 2008 Annual Meeting Class
Director Whose Term Expires 2008 Annual Meeting Shareholders Directors Whose Term Expires 2009 Annual Meeting Shareholders
Directors Whose Term Expires 2010 Annual Meeting Shareholders Directors Whose Terms Expire 2006 Annual Meeting Class
Directors Whose Terms Expire 2007 Annual Meeting Class Disclosure Controls Procedures
Discussion 2004 Compensation Chief Executive Officer Discussion 2005 Compensation Chief Executive Officer
Discussion Revenue Expense Dispute Resolution
Duration Plan Dystrophy Association
Effect Certain Fundamental Changes Other Reclassification Consolidation Merger Effect Termination
Effective Date Amended Restated Plan Effective Date Plan
Eligibility Employee Benefit Plans
Employee Stock Purchase Plan Employees
Engel Novitt Llp Potential Savings Might Realized Medicare Entering New Market Area Contours Unclear Result Material
Entire Agreement Party Beneficiaries Entry Material Definitive Agreement
Environmental Matters Equity Compensation Plan Information
Equity Incentive Agreements Estimates
Even Obtain Approval Products United States European Union Events Default
Events Default Repurchase Rights Exact Name Registrant Specified Charter
Except Per Share Amounts Except Per Share Data
Except Per Share Data-unaudited Exchange Act 1934
Excluded Assets Excluded Products
Executive Officer Option Grants Executive Officers
Executive Officers Other Those Also Directors Exhibits
Expanded Access Program Patients Italy Als Explanatory
Extension Time Waiver Etc Extreme Insulin Resistance
Face Uncertainties Related Patents Proprietary Technology Materially Adversely Facilities
Fair Value Financial Instruments Fasb Issued Interpretation Accounting Uncertainty Income
Fda Approval Process Fda Approves Insmeds Orphan Drug Iplex Treatment Severe
Fda Extends Pdufa Date Somatokine 2005 Fda Not Establish Specific Guidelines Arrive Consensus Regarding
Federal Income Tax Considerations Stock Purchase Plan Fees Billed Ernst Young Llp
Fees Expenses Fewer Children Severe Primary Igfd Estimate Not Generate
Fiduciary Relationship Financial Appendix Definitions
Financial Information Financial Results Full-year 2007
Financial Statements Exhibits Financing Activities
Focusing Markets Unmet Needs Follow-on Biologics
Form 10-k Form 10-q
Form Conversion Notice Former Amgen Manufacturing Executive Joins Insmed
Former Veteran Amgen Executive Forward Looking Statements
Forward-looking Statements Forward-looking Statements Include Not Limited Plans Develop Market
Free Writing Prospectuses Frequency Reporting
Fujisawa Pharmaceutical Ltd Full-year 2007 Recent Highlights
Further Assurances General
General Provisions Gne Tercicas Opt-in Right Permitted Indications
Governance Governing Law Provisions Waiver Jury Trial
Government Regulation Governmental Approvals
Governmental Approvals Consents Grants Plan-based Awards
Grants Plan-based Awards 2006 Grants Plan-based Awards 2007
Gross Proceeds 130 Growth Failure Due Ghis Resulting Igf-i Deficiency
Growth Hormone Insensitivity Syndrome Growth Strategy Includes Acquiring Complementary Businesses Technologies Not
Half 2006 Hars
Hatch-waxman Act Held 2005
Held 2006 Held 2007
Held 2008 Hereby Found Adjudicated Ordered
History Operating Losses Expectation Generate Foreseeable Future Not Http Phxcorporate-irnet Playerlinkzhtmlc122332swme1907655
Illegal Promote Iplex Uses Other Those Approved Regulatory Inability Compete Successfully Materially Adversely Affect Business Financial
Inancial Ppendix Income Taxes
Indemnification Indemnification Contribution
Index Index Report Form 10-k
Information Annual Meeting Information Included Report
Information Relating Election Director Information Relating Election Directors
Information Relative Designation Auditors Infringement Claims
Infringement Party Rights Infringement Patents Parties
Ins-19 Granulocyte Colony Stimulating Factor Ins-20 Pegylated Granulocyte Colony Stimulating Factor
Insm-18 Insmed
Insmed Announces 2008 Financial Results Insmed Announces Additional Information Compliance Nasdaq Rules
Insmed Announces Financial Results Six-months 2008 Insmed Announces Full-year 2007 Financial Results
Insmed Announces Listing Transfer Nasdaq Global Market Capital Insmed Cephalon Sign License Agreement Allowing Distribute Patent
Insmed Corporate Information Insmed Expected Launch Follow-on Biologics Market
Insmed Inc Reports Financial Results Insmed Incorporated
Insmed Incorporated Officers Bonus Plan Insmed Incorporated Released Following Statement Response Recent Actions
Insmed Incorporated Reports Financial Results 2006 Insmed Patent Litigation Verdict Announced
Insmed Patent Portfolio Insmed Prices Equity Offering
Insmed Receives Nasdaq Deficiency Notice Relating Minimum Bid Insmed Safe Harbor Statement
Insmed Sues Tercica False Advertising Insmeds Royalty Obligations Tercica Gne
Installments Principal Shall Become Due Follows Instruction Withhold Authority Vote Such Nominee Write Name
Insurance Interest Payments
Internal Control Over Financial Reporting Interpretation
Inventories Investor Conference Call
Investor Questionnaire Iplex
Iplex Hars Iplex Launch Marked Product Shipments Patients States Across
Iplex Only Product Respect Completed Research Development Stage Iplex Pipeline -targeted Research
Iplex Retinopathy Prematurity Iplex Short-stature Market
Iplex Worldwide License Development Agreement Iplexs Approved Indication
Italian Health Authority Refuse Pay Iplex Used Patients Italian Ministry Health Requests Iplex Treatment Als Lou
Italy Requests Iplex Als Patients Joint Commercialization Committee
Joint Development Committee Joint Press Release
Judge Cites Deficiencies Tercicas Genentechs Complaint Landlord
Landlords Remedies Lead Development Follow-on Biologics
Lease Addendum Number Leases
Legal Proceedings License Collaborative Agreements
Licenses Insmed Limitation Certain Transactions
Limitation Deductions Liquidity Capital Resources
Litigation Settlement Reached Between Tercica Genentech Insmed Long Term Growth Strategy Include Acquiring Complementary Businesses
Long-term Viability Growth Depend Successful Development Commercialization Products Lower Sga Expenses Help Narrow Loss
Managements Discussion Analysis Financial Condition Results Operations Managements Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Edge
Market Price Stock Been Continue Highly Volatile Not Marketing Sales
Meetings Board Mergers Other Transactions
Miscellaneous Muscular Dystrophy Association
Muscular Dystrophy Association Mda Myotonic Muscular Dystrophy
Myotonic Muscular Dystrophy Clinical Study Myotonic Muscular Dystrophy Research
Napo Nasdaq
Nasdaq Capital Market Cease List Common Stock Cause Nasdaq Rules
Need Additional Funds Future Continue Operations Face Uncertainties Need Collaborative Relationships Successful Unable Form Materially Adversely
Net Loss Per Share New Plan Benefits
Nominations Governance Committee Nominees
Non-als Portion Set Forth Such Royalty Equal Aggregated Not Able Manufacture Sufficient Quantities Products Meet Supply
Not Accurately Predict Protection Afforded Patents Proprietary Technology Not Completed Research Development Stage Product Candidates Unable
Notice Annual Meeting Shareholders Notice Defaults Shall Notify Holder Promptly Event Not
Notice Non-liability Mechanics Liens Notice Option Exercise
Notices Notices Debt Option Warrant Holders
Number 0-30739 Number Shares Subject Option
Obligations Seller Post-closing Period Off-balance Sheet Arrangements
Oint Etter Hysicians Oncology Programs Insm-18 Rhigfbp-3
Ongoing Clinical Study Ongoing Clinical Trial
Operate Highly Competitive Environment Unable Adapt Compete Successfully Operating Expense Exclusions
Operational Restructuring Opinion Financial Advisor
Opt-in Partys Co-promotion Option Product Indication Opt-in Partys Sole Promotion Option Product Indication
Opt-in Rights Procedures Option Amendments
Option Grants 2004 Option Grants 2005
Option Renew Lease Term Optional Redemption Principal Installments
Options Order Regain Compliance Minimum Bid Price Requirement Nasdaq
Order Regain Compliance Minimum Bid Price Rule Required Ordered
Organization Standing Corporate Power Orm Onsent Udgment Ermanent Njunction
Orm Roceedings Ettlement Greement Orphan Drug Designation Exclusivity
Other Events Other Indications Iplex Development
Other Information Other Matters
Other Reclassification Consolidation Merger Sale Other Regulatory Requirements
Outstanding Equity Awards Overall Objectives Executive Compensation Programs
Overview Ownership Operations Purchaser
Parachute Payments Part
Part Financial Information Partial Unenforceability
Party Patents Patent Portfolio
Patents Proprietary Rights Patents Proprietary Rights Patent Portfolio
Payment Expenses Payments Due
Peer Group Performance Goals
Performance Graph Performance Share Awards
Pharmacia Pharmacia Inc
Philosophy Overview Planned Clinical Study
Potential Payments Termination Change Control Preferred Stock Purchase Rights
Press Release Principal Executive Offices Insmed Incorporated
Principal Payment Notes Principles Consolidation
Principles Reporting Product Pipeline
Product Platforms Products Currently Just Completed Research Development Stage Unable
Products Currently Research Development Stage Unable Commercialize Them Products Fail Achieve Market Acceptance Reason Such Failure
Products Fail Pre-clinical Clinical Trials Cannot Enroll Enough Products Fail Preclinical Clinical Studies Cannot Enroll Enough
Products Fail Preclinical Clinical Trials Cannot Enroll Enough Promising Results Observed Ongoing Open Label Trial
Property Equipment Property Plant Equipment
Proposals 2006 Annual Meeting Proposals 2007 Annual Meeting
Proposals 2008 Annual Meeting Proposals 2009 Annual Meeting
Proprietary Protein Platform Prosecution Patents
Proxy Solicited Behalf Board Directors Properly Executed Voted Public Announcements
Public Stock Offering Publication
Purchase Agreement Purchase Sale Delivery Shares
Purchaser Agreement Signature Page Purchaser Information
Purposes Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Data Recent Accounting Pronouncements
Recent Highlights Recitals
Recommendation Registered Direct Offering
Registrants Business Operations Registrants Telephone Number Including Area Code
Registration Rights Agreement Registration Rights Agreement Signature Page
Registration Rights Agreements Regulation Disclosure
Regulatory Bodies Regulatory Matters
Reimbursement Policies Changes Health Care System Adversely Affect Reimbursement Underwriter Expenses
Related Party Transactions Release
Release Security Assumed Boulder Leases Releases Waiver
Rely Collaborative Relationships Success Unable Form Materially Adversely Remainder Force Effect
Remedies Rent Other Amounts Payable
Rent Schedule Renewal Report Form 10-k
Report Form 10-q Report Independent Registered Public Accounting Firm
Representations Warranties Repurchase Event
Required Conduct Broad Long-term Clinical Studies Address Concerns Required Conduct Broad Long-term Clinical Trials Address Concerns
Research Development Research Development Activities
Research Development Costs Research Development Manufacturing Activities Involve Hazardous Materials Expose
Reservation Shares Fully Paid Listing Common Stock Restricted Stock Units
Restrictive Covenants Restructuring Plan
Results Operations Results Operations Financial Condition
Retained Liabilities Revenue Recognition
Review Nasdaq Staff Determination Revoking Proxy
Rhigfbp-3 Richmond
Richmond 2008 Richmond 2009
Right Participate Future Financings Right Purchasers Participate Future Transactions
Rights Granted Tercica Gne Risk Factors Related Business
Risk Factors Relating Business Risks Uncertainties
Role Compensation Committee Making Decisions Role Igf-i Igfbp-3 Cancer
Role Igf-i Igfbp-3 Glucose Metabolism Role Igf-i Igfbp-3 Growth
Romotion Greement Erms Onditions Rooftop License
Royalties Due Non-als Portion Royalty Payments Shall Paid Royalties Other Named Patient Sales Pursuant Off-label
Royalty Payments Non-profit Share Indications Rule 13a-14 15d-14 Certification
Sale Purchase Purchased Assets Sales Tracking Methodology
Sarbanes-oxley Act 2002 Sarbanes-oxley Act 2003
Schedule Securities Registered Pursuant Act
Securities Trading Markets Security Ownership Certain Beneficial Owners
Security Ownership Certain Beneficial Owners Management Security Ownership Management
See Accompanying Notes Seeks Immediate Dismissal Summary Judgment Claims
Segment Information Selection Peer Companies Benchmarks
Senior Convertible Due 2008-2010 Separate Copies Beneficial Holders
Settlement Agreement Settlement Agreement Restructuring
Settlement Agreement Tercica Genentech Terminated Consent Order Court Settlement Agreement Tercica Genentech Was Terminated Consent Order
Settlement License Development Agreement Settlement Litigation Tercica Genentech
Severability Share Limitations
Shareholders Record Shares Subject Option
Sharing Operating Profit Product Opt-in Indication Signature
Signature Holder Signature Page Follow
Signature Page Follows Signature Page Placement Agency Agreement
Signature Page Settlement License Development Agreement Signature Pages Follow
Signatures Since Limited Operating History Losses Expectation Generate Foreseeable
Solicitation Proxies Solvency Fair Consideration Fraudulent Conveyance
Source Insmed Incorporated Specific Performance
State Other Jurisdiction Incorporation State Takeover Statutes
Stipulated Final Judgment Stipulated Findings Fact Conclusions Law
Stipulated Order Permanent Injunction Stock Awards
Stock Compensation Expense Stock Options
Stock Options Restricted Awards Stock Purchase Plan Benefits
Stock-based Compensation Stock-based Compensation Expense
Study Description Subject Product Liability Claims Products Harm People Only
Submission Matters Vote Security Holders Subscription Agreement
Subsequent Events Subsidiaries Insmed Incorporated
Successors Sufficient Funds
Summary Amended Restated Plan Summary Significant Accounting Policies
Summary Stock Purchase Plan Surrender Holding Over
Survival Table Calculating Aggregated Royalty Amount
Taisho Pharmaceutical Ltd Tax Aspects Internal Revenue Code
Taxes Taxes Assessments
Telephone Internet Vote Authorizes Named Proxies Shares Same Tercica
Tercica Genentech Resolved Trial Tercica Safe Harbor Statement
Tercicas Gnes Right Terminate Term Lease
Term Overview Termination Rights Termination
Termination Agreement Termination Agreement Entirety Insmed Tercicas Gnes Material Breach
Termination Agreement Permitted Indication Insmed Termination Representations Warranties
Terms Conditions Purchase Units Third-party Claims Products Infringe Proprietary Rights Materially Adversely
Third-party Patents Timely Manner Shares Warrants Not Delivered Closing Investor
Twelve-months 2005 Tzamal Pharmaceutical
Unable Continue Build Sales Marketing Distribution Capabilities Materially Underwriting Agreement
United States University California San Francisco
University Rochester School Medicine Dentistry Unobservable Inputs Level
Unregistered Sales Equity Securities Updates Drug Development Progress
Utility Operating Maintenance Repair Expenses Uva Patent Foundation
Virginia Vote
Vote Not Required Approval Vote Required Approval
Warrant Not Transferred Except Provided Warrants
Whereas Parties Avecia Agreed Date Hereof Enter Certain Withholding Taxes
Worldwide Pre-approval Iplex Sales 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki